European manufacturing sites

FINE CHEMICALS FOR PHARMACEUTICALS

from R&D to Pilot and Industrial

Contact us at:

www.moehs.com

More than 160 reactors running

Capacity up to 1100m3

750 high specialized employees

Fabrication from R&D to pilot, to Industrial scale

Skills

Sites of Moehs group

BENECHIM S.p.r.l

08191 Rubí (Belgium)

More information

High quality

standards

Visit us at: 

CphI Madrid, 9-11 October, stand 5D30

Quality Assurance

Regulatory Affairs

Technical Assistance

Quality Control

Sites approval: FDA, J-PMDA, C-FDA, KFDA, TGA, EMA

GMP & ICH Q7A compliance

Compliance to USP, Eur. Ph., JP, ND

More than 30 CEPS issued

European manufacturing sites

Sites of Moehs group

NORCHIM S.A.S.

60340 Saint Leu d'Esserent (France)

more information

BENECHIM S.p.r.l

08191 Rubí 

(Belgium)

More information

CHEMISCHE FABRIK BERG GmbH

06749 Bitterfeld - oflen (Germany)

MOEHS CANTABRA, S.L.

39313 Polanco (Spain)

more information

PROTEOS BIOTECH, S.L.

02006 Albacete (Spain)

MOEHS IBERICA

Headquarters

08191 Rubí (Spain)

More information


COPRIMA

08213 Polinyà (Spain)

More information


MOEHS CATALANA

08191 Rubí (Spain)

More information


MOEHS BCN

08755 Castellbisbal (Spain)

More information

Skills

More than 160 reactors running

Capacity up to 1100m3

750 high specialized employees

Fabrication from R&D to pilot, to Industrial scale

High quality standards

Sites approval: FDA, J-PMDA, C-FDA, KFDA, TGA, EMA

GMP & ICH Q7A compliance

Compliance to USP, Eur. Ph., JP, ND

More than 30 CEPS issued

Quality Assurance

Regulatory Affairs

Technical Assistance

Quality Control

Visit us at 

CphI Madrid , 9-11 October, stand 5D30

Go to article: Home | Trust In Big PharmaGo to article: EditorialGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: FreudenbergGo to article: The Pharma Industry BriefingGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: Humira: the highs and lows of the world’s most successful drug Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Gene therapy: talking smart solutions with Bluebird BioGo to article: Moehs Iberica Company InsightGo to article: Moehs Iberica SLGo to article: A research headache: improving the understanding of chronic migraine Go to article: SensitechGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Philanthropy in pharma: a look inside the ISPE FoundationGo to article: DelSiTechGo to article: Novel Oral Therapies Are An Unmet Need For Ulcerative ColitisGo to article: PhoenixGo to article: FDA removes key barrier to US biosimilar developmentGo to article: Nipro PharmaPackagingGo to article: Pfizer price hikes: do rare cancer drugs warrant higher prices?Go to article: AlpexGo to article: Head-to-head: competing for the most effective psoriasis drugGo to article: Mecmesin Company InsightGo to article: MecmesinGo to article: Takeda to seek label expansion for Ninlaro in multiple myelomaGo to article: Capsugel Company InsightGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s EpidiolexGo to article: EcocoolGo to article: Abiogen PharmaGo to article: Illegal online pharmacies: how endemic are they?Go to article: Global Freight Solutions LtdGo to article: The boom in medical cannabis research is set to continueGo to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Population boom will boost acute stroke market, particularly in ChinaGo to article: Pall BiotechGo to article: Cryo StoreGo to article: Watch Alibaba instead of Amazon in healthcareGo to article: WIKA - Disaster preventionGo to article: AstraZeneca’s Lynparza maintains lead in PARP inhibitor raceGo to article: G.F.Go to article: Erdmann Design SwitzerlandGo to article: CMV presents a serious concern in HIV+ personsGo to article: BEA TechnologiesGo to article: BaxterGo to article: bDMARD therapy: adherence in the first year is key to successGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: End the struggle: pathways to HEAL the opioid crisisGo to article: LaudaGo to article: AbbVie poised to overtake Gilead as hepatitis C leaderGo to article: ILC Dover IncGo to article: ViiV results show the importance of INIs to future HIV treatmentGo to article: PfanstiehlGo to article: Novartis acquires rights to atopic dermatitis candidate MOR106Go to article: Niconex Medical LtdGo to article: EventsGo to article: Next issue